An Emergency Medicine Broadsheet
·Phoenix·
Est. MMXXVI
Blue Fish Med · Today's Topic
Hemophilia
In hemophilia, a seemingly modest injury can conceal a bleed that expands until it threatens a joint, airway, or life. Replacing the missing factor early can prevent irreversible harm.
Also known asfactor VIII deficiency · factor IX deficiency · Christmas disease · hemophilia A · hemophilia B
A 16-year-old sits rigidly on the edge of the stretcher, one knee held slightly bent beneath a school uniform. His mother says the pain began after practice, though no one saw a collision. The joint is warm and visibly fuller than the other; he watches the doorway as the nurse reaches for a blood draw. The next move has not yet been made.
— What’s your move? Read on.
Before you read
Which bleeding sites must be treated before confirmation?
When is desmopressin an option—and when is it not?
When to Think of It
Think hemophilia in a patient with a known diagnosis, family history, or unexplained deep-tissue bleeding—especially hemarthrosis, muscle hematoma, prolonged bleeding after a procedure, or intracranial symptoms after even minor trauma. Hemophilia A is factor VIII deficiency; hemophilia B is factor IX deficiency. The patient’s product, severity, inhibitor status, and written treatment plan matter.
Sick or Not Sick
The key fork is critical-site or major bleeding versus stable, noncritical bleeding. Suspected intracranial, neck/throat, gastrointestinal, retroperitoneal, or major muscle bleeding is an emergency: treat on suspicion and involve hematology immediately; do not wait for laboratory confirmation or imaging.
The First Fifteen Minutes
Known or suspected significant bleed: Give the patient’s prescribed factor product promptly, ideally using their individualized plan. If unavailable, for a major bleed give factor VIII 50 IU/kg IV for hemophilia A, or factor IX 100–120 IU/kg IV for hemophilia B, targeting near-normal factor activity; product recovery varies, especially for factor IX, so confirm dosing with hematology/pharmacy or institutional protocol. Factor replacement restores clot formation.
Mild hemophilia A with a documented prior response and noncritical bleeding: Consider desmopressin 0.3 mcg/kg IV (maximum 20 mcg) over 20–30 minutes; it releases stored factor VIII/von Willebrand factor. Do not use for hemophilia B, severe hemophilia A, or without knowing response; restrict free water and monitor sodium.
Mucosal bleeding as an adjunct: Consider tranexamic acid 1 g IV every 8 hours or 1–1.5 g PO three times daily, because antifibrinolysis stabilizes formed clots. Avoid for upper-tract hematuria because obstructing clots can form; check a reference/protocol for renal adjustment and duration.
Obtain CBC, type and screen, PT/INR, aPTT, factor activity, and inhibitor history, but do not delay factor for results when the bleed is serious. Avoid IM injections, unnecessary arterial punctures, and nonselective NSAIDs.
Definitive Care & Disposition
Consult hematology early; confirm factor level and inhibitor status, arrange repeat factor dosing and monitoring, and image the suspected site when indicated. Major or critical-site bleeds require admission—often ICU for airway, neurologic, or hemodynamic risk. A stable joint bleed may be managed with the patient’s hemophilia team and a reliable home plan after factor replacement, reassessment, and clear return precautions. In patients with inhibitors, specialist-directed bypassing therapy may be needed; emicizumab is prophylaxis, not acute bleed treatment.
How This One Kills
Waiting for imaging or coagulation results before giving factor in a suspected intracranial or airway bleed can turn a preventable bleed into irreversible neurologic injury or airway loss.
The Differential — What Else Looks Like This
Septic arthritis — fever, marked pain with passive motion, or systemic illness raises concern; mistaking it for hemarthrosis can delay joint-saving antibiotics and drainage.
von Willebrand disease — mucocutaneous bleeding and abnormal von Willebrand testing point away from isolated factor VIII/IX deficiency; the wrong replacement strategy may fail.
Acquired factor VIII inhibitor — new spontaneous soft-tissue bleeding and isolated prolonged aPTT in someone without a bleeding history; treating as inherited disease can delay inhibitor-directed care.
The Second-Day Story
In an older adult with no personal or family bleeding history, new extensive bruising, muscle hematomas, or post-procedural bleeding may reflect an acquired factor inhibitor rather than inherited hemophilia. In a patient already receiving prophylaxis, a bleed may be subtle and routine aPTT may be misleading, particularly with emicizumab. Let the bleeding pattern, medication/product history, factor assay, and hematology input guide the next step.
Back to Our Patient
Back to our patient: the 16-year-old with the warm, swollen knee has known severe hemophilia A and a painful atraumatic hemarthrosis, with stable vital signs and no head injury or other bleeding. Recognize the likely joint bleed, then risk-stratify: this is urgent but not currently a critical-site bleed. Check his treatment plan and inhibitor history, give prescribed factor VIII promptly (or 25–50 IU/kg IV if the plan is unavailable, with hematology/pharmacy guidance), reassess pain and joint findings, and avoid unnecessary invasive procedures. After hematology coordination and a reliable replacement/follow-up plan, disposition depends on response and the ability to manage safely at home.
Patient Presentation to Attending
How you’d present this patient on the floor — tight, pertinent positives and negatives, no rambling
“This is a 16-year-old with severe hemophilia A presenting with atraumatic right-knee pain and swelling. It began after soccer practice, but neither he nor his mother reports a collision or fall. He is afebrile and hemodynamically stable, with no head strike, other bleeding, or neurologic symptoms. The right knee is warm and fuller than the left, with painful flexion but intact distal perfusion and sensation. This is most consistent with acute hemarthrosis without current evidence of a critical-site bleed. I’m checking his factor plan and inhibitor history, giving his prescribed factor VIII now, and contacting hematology. I’ll reassess the joint and disposition him only after he has an adequate home-treatment and follow-up plan.”
Study Directive
From memory, distinguish hemophilia A from B and list the bleeding patterns that demand immediate factor replacement.
Work three factor-dose calculations: one joint bleed, one critical-site bleed, and one case with a product-specific recovery caveat.
Review your institution’s pathway for hemophilia with inhibitors and identify how emicizumab affects coagulation testing.
Srivastava A, Santagostino E, Dougall A, et al. · Haemophilia, 2020 · PMID 32744769 · cited 2044×
Guidance on factor replacement and management of acute bleeding helps ED clinicians treat suspected serious hemorrhage without delaying for confirmatory testing.
In a palliative emergency, the central task is not to do everything possible—it is to find the care that best matches the patient’s goals while relieving...
Also known aspalliative emergency · end-of-life emergency care · terminal illness emergency
A 74-year-old rests forward on a canvas chair in a small rural emergency department, fingers gripping the fabric as each breath catches. Her daughter places a folded hospice folder on the counter and asks whether the ambulance can take her home. The nearest hospital with an ICU is more than an hour away. The team has not yet agreed on what the patient wants this night to look like.
Before You Read
What do you need to clarify before choosing a treatment or transport?
Which reversible causes are worth treating within this patient’s goals?
How can you relieve distress quickly without defaulting to escalation?
Why It Matters
In a palliative emergency, the central task is not to do everything possible—it is to find the care that best matches the patient’s goals while relieving suffering. Rural distance and limited resources make early, explicit decisions especially important.
When to Think of It
Consider a palliative emergency when a patient with serious illness presents with distressing dyspnea, pain, agitation, nausea, bleeding, or caregiver crisis—whether or not they are enrolled in hospice. A hospice or POLST document informs care but does not replace a conversation about the patient’s current wishes.
Sick or Not Sick
The key call is what level of intervention the patient wants and can benefit from now. Assess capacity; ask the patient, when possible, about acceptable outcomes, desired symptom relief, and preferences about hospitalization, ventilation, CPR, and transport. Confirm advance directives and surrogate authority; do not equate DNR with “do not treat.”
The First Fifteen Minutes
Address immediate threats and ask the patient directly what matters most; clarify hospice contact, advance directive/POLST, decision-maker, and acceptable destination. Offer tele-hospice, tele-palliative, or regional specialist support when available.
Distressing dyspnea or pain in an opioid-naïve adult: Give morphine 2–4 mg IV every 5–15 minutes, titrating to comfort and respiratory status; it reduces the perception of breathlessness and pain. In significant renal impairment, consider fentanyl 25–50 mcg IV every 5–10 minutes instead, because it has less problematic active-metabolite accumulation; titrate cautiously.
Persistent panic or anxiety after symptom relief: Consider lorazepam 0.5–1 mg PO or IV, reassessing before repeat dosing; it can reduce severe anxiety but may worsen sedation or delirium, especially with opioids.
Agitated delirium causing distress: Consider haloperidol 0.5–1 mg PO or IV every 4–6 hours as needed, after checking for correctable causes and QT risk; it can reduce distressing agitation. Check a reference or local protocol for route-specific use and repeat dosing.
Give oxygen for hypoxemia or when the patient finds it comforting; do not force a mask that increases distress. Treat reversible causes only when consistent with the patient’s goals.
Definitive Care & Disposition
Coordinate with the patient’s hospice or palliative team, caregiver, and receiving facility. If symptoms can be controlled and the patient prefers home, arrange safe transport, medications, equipment, and a direct handoff. If symptoms remain uncontrolled, the home situation is unsafe, or the patient wants hospital-based care, admit or transfer at the level needed to achieve the agreed goals. Document the patient’s preferences, capacity, surrogate, treatments offered, and why the chosen disposition is goal-concordant.
How This One Kills
Treating a DNR order as a ban on all active symptom relief—or, conversely, intubating by default before clarifying goals—can produce suffering and an outcome the patient explicitly wanted to avoid.
The Atypical Presentation
The patient may not be able to speak for themselves, symptoms may be described by a caregiver, or a copied directive may no longer reflect current wishes. Look for changes from baseline, medication timing, and nonverbal distress; assess capacity and seek the legally appropriate surrogate. When preferences are uncertain, treat distress, avoid irreversible escalation while clarifying goals, and use available hospice or specialist support.
Back to Our Patient
Back to our patient: the 74-year-old gripping the canvas chair has advanced lung cancer and severe breathlessness; she is alert, has capacity, and says she wants relief but no intubation or ICU transfer. Recognize the emergency as distressing dyspnea, then risk-stratify around her stated goals rather than the distance to the tertiary hospital. With hypoxemia and no indication she wants burdensome escalation, provide comfort-focused care, titrate IV morphine to relief, and involve hospice by phone while assessing whether a reversible cause can be treated in keeping with her wishes. Once her breathing is more comfortable, arrange the destination and transport she prefers, with a direct hospice handoff and an agreed plan for symptoms en route.
Patient Presentation to Attending
“This is a 74-year-old with advanced lung cancer presenting with severe dyspnea and a request for symptom relief. She is alert, has decision-making capacity, and states that she wants comfort but does not want intubation or ICU care. Her daughter brought the hospice paperwork; I’m confirming the current plan with the patient and hospice rather than treating the document as a substitute for her wishes. She is tachypneic and hypoxemic, with increased work of breathing but no acute confusion or recent opioid dosing. I’ll titrate IV morphine to comfort, use oxygen if it relieves distress, and assess for reversible causes she would want treated. I’m contacting hospice now and will arrange goal-concordant transport or admission if we cannot control symptoms safely here.”
Study Directive
Practice a one-minute goals-of-care conversation that asks about acceptable outcomes, CPR, ventilation, hospitalization, and preferred destination.
Review your state’s POLST and surrogate decision-making rules; identify how to reach local hospice after hours.
Rehearse opioid titration for dyspnea in an opioid-naïve patient and write down the changes you would make for opioid tolerance or renal impairment.
Key Medications
Morphine: 2–4 mg IV every 5–15 minutes, titrated for opioid-naïve adults with dyspnea or pain. For opioid-tolerant patients, use their baseline exposure and individualized rescue plan rather than a fixed naïve dose.
Fentanyl: 25–50 mcg IV every 5–10 minutes as a cautious alternative, especially when renal impairment makes morphine less suitable; titrate to response.
Lorazepam: 0.5–1 mg PO or IV for persistent severe anxiety; reassess sedation and delirium risk before repeating.
Haloperidol: 0.5–1 mg PO or IV every 4–6 hours as needed for distressing agitation; QT risk and dosing practices vary, so check a local protocol/reference.
Pediatric palliative dosing is weight-based and requires pediatric palliative-care guidance.
High-Yield Pearls
A patient with capacity speaks for themselves even when family or old paperwork suggests a different plan.
A DNR order limits CPR in cardiac arrest; it does not automatically rule out antibiotics, fluids, oxygen, analgesia, or hospital care.
If the patient’s goals are unclear, relieve suffering while seeking clarification; avoid irreversible escalation by default.
The Mimics
Opioid toxicity — depressed consciousness and hypoventilation after a recent dose suggest medication effect; missing it can worsen respiratory failure, while reflexive reversal can precipitate severe pain or withdrawal.
Pulmonary edema — abrupt orthopnea, crackles, and volume overload may identify a treatable cause; overlooking it can prolong distress when treatment is desired.
Sepsis — infection with hypotension or altered mental status may be reversible within the patient’s goals; assuming all decline is “expected” can deny wanted treatment.
Terminal delirium — fluctuating attention and altered perception differ from simple anxiety; escalating sedatives without recognizing delirium can deepen confusion.
Board Question
A hospice patient with advanced cancer arrives with severe dyspnea. She is alert, has capacity, and says she wants symptom relief but does not want intubation. What is the best next step?
AWithhold opioids because they may reduce respiratory drive
BTreat the DNR as a refusal of all medical care
CClarify goals, treat distress with carefully titrated opioid, and coordinate with hospice
DIntubate first, then discuss her preferences with family
Reveal answer
Correct: C
A DNR order does not mean “do not treat,” and a capable patient’s stated preferences should guide care. Carefully titrated opioids can relieve dyspnea while the team coordinates a goal-concordant plan.
For rural patients admitted from the ED with serious illness, video palliative consultation may provide specialist help with symptom distress when local services are limited.
Sickle cell disease can turn a familiar pain crisis into acute chest syndrome, stroke, or sepsis. Early recognition and timely, carefully chosen treatment...
Also known assickle cell anemia · sickle cell anemia disease · SCD · hemoglobin SS disease
A 28-year-old leans over the stretcher, one hand pressed against his ribs as the monitor chirps beside him. He says the pain began in his back yesterday, but today each breath feels shorter. His temperature is 38.3°C, and the pulse-oximeter reads 89% on room air. The chest image has not yet returned.
Before You Read
What finding separates uncomplicated pain from a life-threatening complication?
Which treatments should begin before imaging is complete?
When is transfusion simple—and when should it be an exchange?
Why It Matters
Sickle cell disease can turn a familiar pain crisis into acute chest syndrome, stroke, or sepsis. Early recognition and timely, carefully chosen treatment can prevent rapid deterioration.
When to Think of It
Consider vaso-occlusive pain in a patient with sickle cell disease and acute pain, but screen for fever, hypoxemia, chest symptoms, neurologic deficit, anemia, and splenic enlargement. Acute chest syndrome (ACS) is a new pulmonary infiltrate plus fever and/or respiratory symptoms; it can evolve after arrival, so reassess.
Sick or Not Sick
The key fork is uncomplicated vaso-occlusive pain versus a complication such as ACS, stroke, sepsis, or acute anemia. Hypoxemia, respiratory distress, new infiltrate, focal neurologic deficit, hypotension, or a major hemoglobin drop means escalation and early hematology involvement.
The First Fifteen Minutes
Severe pain: Use the patient’s individualized pain plan when available. For an opioid-naïve adult, give morphine 0.1 mg/kg IV (usual initial maximum 10 mg) or hydromorphone 0.5–1 mg IV, then reassess and repeat every 15–30 minutes as needed; opioids relieve severe vaso-occlusive pain. Opioid-tolerant patients may need higher individualized doses.
Pain requiring an adjunct without renal injury, bleeding risk, or other contraindication: Give ketorolac 15 mg IV once; it reduces inflammatory pain. Avoid routine NSAIDs in renal dysfunction, volume depletion, or bleeding risk.
Suspected ACS or pneumonia: Give ceftriaxone 1–2 g IV every 24 hours plus azithromycin 500 mg IV or PO every 24 hours, because ACS often has an infectious trigger and atypical pathogens require coverage. Tailor to allergy, local guidance, and infection findings.
Give oxygen for hypoxemia; obtain CBC/reticulocytes, type and screen, blood culture if febrile, ECG, and chest imaging. Use incentive spirometry and reassess respiratory status. Avoid routine large fluid boluses; give fluids only for dehydration or poor intake, guided by examination.
Suspected stroke: Activate the stroke pathway and arrange urgent exchange transfusion with hematology; do not delay specialist coordination for imaging completion. If exchange is unavailable promptly, discuss simple transfusion as a bridge, avoiding excessive hemoglobin elevation.
Definitive Care & Disposition
Admit patients with ACS, hypoxemia, stroke, sepsis, significant anemia, or uncontrolled pain. ACS management includes oxygen as needed, antibiotics, incentive spirometry, analgesia that preserves ventilation, and early hematology consultation. Simple transfusion may be appropriate for symptomatic acute anemia or selected ACS; exchange transfusion is favored for severe/progressive ACS or acute stroke. Use antigen-matched, leukoreduced, HbS-negative red cells according to local transfusion protocol; avoid transfusion for uncomplicated pain alone. Consider ICU care for escalating oxygen or ventilatory support, shock, or neurologic deterioration.
How This One Kills
Repeated opioid dosing without reassessing ventilation and oxygenation can obscure evolving ACS; missing the transition from pain crisis to respiratory disease is a dangerous failure.
The Atypical Presentation
Children, older adults, and patients with chronic organ damage may present with little fever or a less dramatic pain report; a falling oxygen saturation or hemoglobin may be the first clue. Patients with recurrent crises can also have a familiar pain pattern that distracts from new ACS or infection. Compare with baseline, check reticulocytes and oxygenation, and repeat chest assessment when symptoms evolve.
Back to Our Patient
Back to our patient: the 28-year-old with rib pain, fever, and room-air saturation of 89% has a new left lower-lobe infiltrate on chest radiograph, meeting criteria for acute chest syndrome. Recognize the transition from pain crisis to ACS; risk-stratify him as sick because of hypoxemia and infection signs. Start oxygen, prompt analgesia that preserves ventilation, ceftriaxone plus azithromycin, incentive spirometry, and early hematology consultation; assess whether transfusion is indicated and escalate to exchange if he worsens. He is admitted for monitoring and treatment, with a higher level of care if oxygen needs or work of breathing increase.
Patient Presentation to Attending
“This is a 28-year-old with sickle cell disease presenting with worsening back and rib pain, fever, and new dyspnea. He reports pain beginning yesterday, but today he is breathing faster and feels short of breath. He is febrile and hypoxemic at 89% on room air, without focal neurologic deficit or hypotension. Chest radiograph shows a new left lower-lobe infiltrate, and his CBC and reticulocyte count are pending. This is acute chest syndrome complicating vaso-occlusive pain, with hypoxemia requiring admission. I’m starting oxygen, titrated analgesia, ceftriaxone and azithromycin, and incentive spirometry, while involving hematology to guide transfusion and escalation.”
Study Directive
From memory, define acute chest syndrome and list the findings that trigger admission and hematology consultation.
Draw a one-page transfusion decision pathway for uncomplicated pain, acute anemia, ACS, and stroke.
Practice an initial opioid plan for both an opioid-naïve patient and a patient with a documented high-dose home regimen.
Key Medications
Morphine: 0.1 mg/kg IV initially (usual maximum 10 mg), with reassessment and repeat dosing every 15–30 minutes as needed; individualize for opioid tolerance.
Hydromorphone: 0.5–1 mg IV initially, titrated to response; dose practices vary with opioid exposure and institutional pathway.
Ketorolac: 15 mg IV once as an adjunct when appropriate; avoid with renal dysfunction, volume depletion, or bleeding risk.
Ceftriaxone: 1–2 g IV every 24 hours for suspected ACS/infection.
Azithromycin: 500 mg IV or PO every 24 hours for suspected ACS; check QT risk and local protocol.
Pediatric doses are weight-based and differ from adult doses; use pediatric pathways and hematology guidance.
High-Yield Pearls
ACS can appear after admission for pain; new hypoxemia or respiratory symptoms demand repeat evaluation, even if the initial chest image was clear.
Do not transfuse uncomplicated vaso-occlusive pain alone; transfusion risks include alloimmunization and hyperviscosity.
A normal oxygen saturation at triage does not rule out evolving ACS—trend it and reassess respiratory effort.
The Mimics
Osteomyelitis — focal bone pain with fever and persistent symptoms suggests infection rather than diffuse vaso-occlusion; missing it delays targeted antibiotics and source evaluation.
Septic arthritis — a hot, focal joint with severe pain on passive range of motion requires evaluation for infection; labeling it a pain crisis can cost the joint.
Pulmonary embolism — sudden pleuritic pain, unexplained hypoxemia, or thrombotic risk may not be explained by ACS alone; confusion can delay anticoagulation and definitive evaluation.
Aplastic crisis — profound anemia with a low reticulocyte count contrasts with hemolysis/typical pain crisis; missing it delays necessary transfusion and evaluation.
Board Question
A patient with sickle cell disease develops acute focal neurologic deficits. What is the best transfusion strategy?
ANo transfusion unless hemoglobin is below 7 g/dL
BSimple transfusion to a hemoglobin of 15 g/dL
CUrgent exchange transfusion with hematology involvement
DTreat pain first and reassess neurologic findings in six hours
Reveal answer
Correct: C
Acute stroke in sickle cell disease requires urgent exchange transfusion to reduce the proportion of HbS while avoiding excessive viscosity. Do not delay specialist coordination or treatment while waiting for the hemoglobin to fall below a threshold.
An emergency-focused reference for recognizing and treating vaso-occlusive pain, acute chest syndrome, and other time-sensitive complications of sickle cell disease.
4 of 4
The Bleeding Hemophiliac
A bleeding disorder turns seemingly minor trauma into a potential critical-site hemorrhage. In a patient with hemophilia and head trauma, the safest...
Also known ashemophilia · factor VIII deficiency · factor IX deficiency · Christmas disease
A 22-year-old arrives with rain still beading on his jacket and a small cut above his eyebrow. He says he slipped on the stairs, but cannot remember the moment he hit the floor. His partner says he seemed fine at first; now he has vomited once and keeps asking what time it is. The team has not yet moved him to imaging.
Before You Read
Which treatment must not wait for a scan?
What is the danger of relying on a normal early examination?
Which history changes the replacement plan?
Why It Matters
A bleeding disorder turns seemingly minor trauma into a potential critical-site hemorrhage. In a patient with hemophilia and head trauma, the safest sequence is to correct the coagulopathy promptly while evaluating the injury.
When to Think of It
Treat any head trauma in a patient with hemophilia as possible intracranial bleeding, even with a normal initial examination. Also treat suspected neck, airway, retroperitoneal, gastrointestinal, or major muscle bleeding as time-critical. Clarify hemophilia type, baseline severity, inhibitor history, prophylaxis, and the factor product available.
Sick or Not Sick
The decisive call is possible critical-site bleeding versus an injury that can be managed as minor. Head trauma with vomiting, confusion, loss of consciousness, severe headache, or an unreliable history is an emergency; give factor before CT and consult hematology.
The First Fifteen Minutes
Head trauma or other suspected critical-site bleed: Give the patient’s prescribed factor immediately. If unavailable, give factor VIII 50 IU/kg IV for hemophilia A, or factor IX 100–120 IU/kg IV for hemophilia B, targeting near-normal activity; verify product-specific recovery with hematology/pharmacy or institutional protocol. Replacement restores clotting before bleeding expands.
Suspected inhibitor or poor response to factor: Contact hematology urgently for a specialist-directed bypassing agent; do not improvise a dose. Emicizumab is not acute bleed treatment, and activated prothrombin complex concentrate can cause serious thrombosis when combined with emicizumab.
Obtain urgent noncontrast head CT, CBC, type and screen, factor activity, and inhibitor information. Do not delay factor for imaging or lab results. Avoid IM injections and unnecessary invasive procedures; assess airway and neurologic status frequently.
Definitive Care & Disposition
Admit for observation and hematology-guided factor coverage when head injury is suspected, even if the first CT is negative; repeat imaging or further evaluation depends on symptoms and specialist guidance. Any intracranial hemorrhage requires admission, ongoing factor replacement, neurosurgical consultation, and often critical-care monitoring. For patients with inhibitors, arrange specialist-directed hemostatic therapy and monitor for thrombosis. A normal early CT does not end the evaluation if symptoms progress.
How This One Kills
Waiting for CT confirmation before factor replacement can allow an occult intracranial bleed to expand during the diagnostic delay.
The Atypical Presentation
A patient may appear well initially, have no obvious external bleeding, or present hours after a low-energy fall. Early neurologic findings and initial imaging can be reassuring even as bleeding evolves. In an older patient or one with cognitive impairment, the injury history may be incomplete; use collateral history and treat the known bleeding risk seriously.
Back to Our Patient
Back to our patient: the 22-year-old with rain on his jacket and a small eyebrow cut has known severe hemophilia A, one episode of emesis, and new confusion after a fall. Recognize possible intracranial hemorrhage; risk-stratify him as a critical-site bleed despite the small external wound and incomplete recollection. Give his prescribed factor VIII immediately—or 50 IU/kg IV if his plan is unavailable while urgently involving hematology—then obtain noncontrast head CT and repeat neurologic assessments. His CT shows a small acute subdural hemorrhage, so he is admitted for factor coverage, neurosurgical consultation, and close monitoring.
Patient Presentation to Attending
“This is a 22-year-old with severe hemophilia A presenting after a fall down stairs with confusion and one episode of vomiting. He has a small eyebrow laceration, but his partner reports new repetitive questioning and he cannot recall the impact. He is hemodynamically stable, with a mildly altered mental status and no focal motor deficit. This is possible intracranial hemorrhage despite the limited external injury, and factor replacement should not wait for imaging. I’m giving his prescribed factor VIII now, obtaining urgent noncontrast head CT, and contacting hematology. CT shows a small acute subdural hemorrhage, so I recommend admission for ongoing factor coverage, neurosurgical input, and serial neurologic examinations.”
Study Directive
Rehearse the first five actions for head trauma in hemophilia, in order, without looking at notes.
Calculate factor VIII and factor IX doses for a 70-kg adult and check each against your local protocol.
Review your hospital’s pathway for inhibitors and identify who to call after hours for emergency factor access.
Key Medications
Factor VIII:50 IU/kg IV for suspected major or critical-site bleeding in hemophilia A; individualize to factor target and product.
Factor IX:100–120 IU/kg IV for suspected major or critical-site bleeding in hemophilia B; recovery varies by product, so confirm with hematology/pharmacy or protocol.
Inhibitor therapy: Dosing depends on inhibitor status, product, and concurrent emicizumab; obtain urgent hematology direction and verify against a specialist protocol.
Pediatric replacement is weight-based; use pediatric hematology guidance and product-specific dosing.
High-Yield Pearls
Treat first when the suspected bleed is intracranial, airway-threatening, or otherwise critical; imaging confirms location, not whether initial replacement was warranted.
A small external wound does not predict the size or location of internal bleeding.
Factor product and inhibitor history can change the effective treatment; find the patient’s emergency plan early.
The Mimics
Concussion without hemorrhage — symptoms may overlap, but hemophilia raises the consequence of an unrecognized bleed; dismissing symptoms as concussion can delay lifesaving replacement.
Alcohol or sedative intoxication — altered mental status may be attributed to substances despite an injury; anchoring can miss intracranial hemorrhage.
Isolated scalp laceration — visible external bleeding can distract from a closed-space bleed; focusing only on the wound misses the more dangerous injury.
Cervical spine injury — neck pain or neurologic findings after trauma may reflect spinal injury; assuming bleeding alone can delay immobilization and imaging.
Board Question
A patient with severe hemophilia B presents after a head injury with vomiting. CT is not yet available. What is the best next step?
AWait for the CT result before giving factor
BGive factor IX promptly and obtain urgent CT
CGive desmopressin because it raises factor IX
DDischarge if the neurologic examination is initially normal
Reveal answer
Correct: B
Suspected intracranial bleeding is a critical-site emergency: replace factor IX promptly and obtain urgent imaging without waiting for confirmation. Desmopressin does not treat hemophilia B.
Suspected intracranial bleeding in a patient with hemophilia warrants immediate factor replacement and urgent imaging, without waiting for CT confirmation.
A quick test of recall from prior editions. Commit to an answer before you check.
From yesterday's edition
A 28-year-old patient has sudden-onset palpitations while at rest. The ECG shows a regular narrow-complex tachycardia at 196 bpm. What’s the diagnosis, and the first move?
Check your answer
Supraventricular Tachycardia / Undifferentiated SVT. If unstable, synchronized cardioversion. If stable regular narrow SVT, use modified Valsalva then adenosine per protocol, obtain post-conversion ECG, and plan follow-up/disposition based on recurrence and risk.
From the October 7 edition
Today, three days ago: Fomepizole. What’s the adult ED dose, and the contraindication you’d most regret missing?
Check your answer
15 mg/kg IV load, then 10 mg/kg IV q12h for 4 doses, then 15 mg/kg q12h until toxic alcohol level/clinical criteria resolved. Dose more frequently during hemodialysis per protocol. Hypersensitivity to fomepizole/pyrazoles.
From the September 30 edition
A patient taking long-term prednisone presents with vomiting, hypotension, hyponatremia, and hypoglycemia. Which is the best next step?
AWait for the cortisol result before giving glucocorticoids
BGive hydrocortisone 100 mg IV now
CGive fludrocortisone alone
DTreat with IV saline only and reassess in 6 hours
Reveal answer
Correct · B
Suspected adrenal crisis with hemodynamic instability requires immediate stress-dose hydrocortisone; draw cortisol and ACTH first only if this does not delay treatment. Saline is also indicated, but fluids alone do not replace deficient cortisol.
Journal Watch
From the FOAMed wire
Notable posts and reviews from the last week, ranked by relevance to today’s lead and source trust.
Journal Feed covers D10 vs D50 for hypoglycemia, virus detection in infants and IBI, and TEE guided chest compressions. The post Journal Feed Weekly Wrap-Up appeared first on emDocs .
Podcast Picks
Two for the shift
Critical Care Perspectives in Emergency Medicine2026-09-01
Brain damage and death from ischemic encephalopathy is common after cardiac arrest. Animal studies and limited observational studies suggest that high oxygen exposure after ROSC may result in neuronal death. As such, it is hypothesized that limiting oxygen exposure (conservative oxygen) many attenuate reperfusion injury and improve outcomes. At present,...
Source
Critical Care Perspectives in Emergency Medicine
Published
2026-09-01
Host
Critical Care Perspectives in Emergency Medicine, Critical Care Perspectives in Emergency Medicine
Epistaxis is usually straightforward—until it isn’t. How can you distinguish an anterior bleed from a dangerous posterior bleed? What’s the best sequence for compression, vasoconstrictors, TXA, cautery and packing?...
Critical Care Corner
Matched to today’s topics
A critical-care reference from LITFL’s Critical Care Compendium, tied to today’s differential.
In mild haemophilia A, desmopressin can raise factor VIII, but a major bleed requires prompt factor replacement.
Desmopressin (DDAVP) is a drug used primarily for diabetes insipidus, haemophilia type A, and von Willebrand's disease.
Pharmacology Corner
Two drugs for the shift
One antimicrobial and one other ED workhorse — selected daily, with sources and last-reviewed dates so every dose is cross-checkable.
Antimicrobial of the Day
Aztreonam
Monobactam (IV)
Indication
Gram-negative and Pseudomonas coverage in patients with severe beta-lactam allergy. Gram-negative spectrum only — no gram-positive or anaerobic activity.
What’s your dose? — reveal dosing & cautions
ED Dose
1–2 g IV q8h. Severe/Pseudomonal infection: 2 g IV q6–8h.
Renal Adjustment
Reduce dose when CrCl < 30 mL/min; HD: supplemental dose after dialysis.
Contraindications
Hypersensitivity to aztreonam.
Interactions
Minimal.
Monitoring
Renal function, CBC.
ED Pearl
Aztreonam has no meaningful cross-reactivity with penicillins or cephalosporins — except ceftazidime, with which it shares a side chain — making it the go-to gram-negative agent in true severe beta-lactam allergy. Pair it with a gram-positive agent when needed.
RSI paralysis, ventilator synchrony paralysis in selected intubated patients, and alternative to succinylcholine when contraindications exist.
What’s your dose? — reveal dosing & cautions
ED Dose
RSI: 1.0–1.2 mg/kg IV using actual body weight in many ED protocols. Lower doses 0.6 mg/kg have slower onset and longer time to ideal intubating conditions.
Renal Adjustment
No formal single-dose adjustment, but duration may be prolonged in hepatic/renal dysfunction.
Contraindications
Hypersensitivity to rocuronium/aminosteroid NMBAs. Cannot intubate/cannot ventilate risk is a clinical contraindication to paralysis without rescue plan.
Continuous sedation/analgesia while paralyzed, train-of-four if ongoing, ventilator/airway security.
ED Pearl
Roc lasts much longer than etomidate or ketamine — paralysis without analgesia/sedation is a never-event you prevent with orders before intubation.
For educational use only. Verify dosing against the FDA label and your institution’s pharmacy resources before administering.
ECG of the Day
Channelopathy
Short QT Syndrome
A persistently short QT with tall peaked T waves in a young patient with syncope or a family history of sudden death is a rare but lethal channelopathy.
The Tracing
A 28-year-old man presents after a syncopal episode and a scare of rapid palpitations. He is healthy, athletic, and has no structural heart disease on prior evaluation; a maternal uncle died suddenly in his thirties. Vitals are normal. His 12-lead catches your eye because the interval from the QRS to the end of the T wave looks unusually compressed, with a very short or almost absent ST segment. The T waves are tall, narrow, and peaked, most striking across the precordial leads. On a rhythm strip taken while his heart rate slowed into the 60s, the short interval does not lengthen the way you would expect. You pull his old tracings to compare.
Short QT interval — known patients had QT <320 ms and QTc <340 ms; QTc <330 ms (men) or <340 ms (women) is considered diagnostic
Peaked T waves, particularly in the precordial leads
Short or absent ST segments
Lack of normal QT lengthening as heart rate slows — a fixed QT that fails to prolong at slower rates
Paroxysmal episodes of atrial or ventricular fibrillation
Pearls
At fast heart rates the calculated QTc can look deceptively normal ('pseudonormal'); capture the abnormality by looking at rest, with serial ECGs or Holter monitoring during relative bradycardia (60-80 bpm).
The most common initial presentation is cardiac arrest (about one-third of cases), and up to 80% have documented atrial fibrillation — so AF in a young patient with a short QT is a red flag, not an incidental finding.
This is on the same channelopathy spectrum as long QT, Brugada, and CPVT; diagnosis leans on symptoms and family history alongside the ECG because there are no formal diagnostic criteria.
Pitfalls
Dismissing a short QT as a measurement artifact or benign variant can miss a substrate whose first manifestation is sudden death — including a possible cause of SIDS in infants.
A pseudonormal QTc at tachycardic rates can falsely reassure; the fixed QT that fails to prolong when the rate slows is the giveaway.
Reaching for class III agents like sotalol or ibutilide is ineffective here due to poor drug binding to the mutated channels; quinidine is the pharmacologic agent of choice, and definitive therapy is an ICD.
At the Bedside
Take a young patient with a persistently short QT and syncope, palpitations, arrest, or a family history of early sudden death seriously: place them on monitoring, obtain serial/resting ECGs to confirm the QT fails to prolong at slower rates, and refer urgently to cardiology/electrophysiology — definitive treatment is ICD implantation, with quinidine as the pharmacologic option.
For educational use only. Verify ECG interpretation against the LITFL entry and your institution’s practice before clinical decision-making.
Case of the Day
From the lead · Hemophilia
Self-Examination
Test Your Understanding
A patient with severe hemophilia A presents after a minor head strike and has a normal neurologic examination. CT is pending. What is the best next step?
AWait for CT before treating
BGive factor VIII promptly and obtain urgent CT
CGive desmopressin regardless of hemophilia severity
DObserve without treatment if the aPTT is normal
Reveal answer
Correct answer · B
A potentially intracranial bleed is a critical-site emergency: give factor VIII on suspicion and obtain urgent imaging without delaying replacement. A normal examination or aPTT does not safely exclude a serious bleed.
Study Pace4 topics today; Issue 88 of 94 — Hematology and Oncology (Week 48)Deadline · June 1, 2026